microRNA-based biomarkers for diagnosis of ALS-FTD

Short title: miRNA biomarkers for ALS-FTD

Iddo Magen^{1,2, \$}, Nancy-Sarah Yacovzada^{1,2, \$}, Jason D. Warren³, Carolin Heller^{3,4}, Imogen

Swift^{3,4}, Yoana Bobeva⁵, Andrea Malaspina^{5,6}, Jonathan D. Rohrer^{3*} Pietro Fratta^{6*} and Eran

Hornstein^{1,2*}

1 Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

2 Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel

3 Dementia Research Centre, and 4 UK Dementia Research Institute, Department of

Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

5 Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of

Medicine and Dentistry, Queen Mary University of London, London, UK.

6 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London,

UK

\$ Equal contribution

* To whom correspondence should be addressed: a.malaspina@ucl.ac.uk; j.rohrer@ucl.ac.uk;

p.fratta@ucl.ac.uk; eran.hornstein@weizmann.ac.il;

Abstract word count: 154

Text word count (excluding title page, abstract, references and figure legends): 5290

No. of items (Figures, Tables, Supplementary items): 8, 2, 6

References: 102

Abstract

The neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) reside on a clinical and pathological continuum. Heterogeneity in clinical presentation too often delays clinical diagnosis and calls for molecular biomarkers to assist diagnosis, including cell free microRNAs (miRNA). However, nonlinearity in the relationship of miRNAs to clinical states and underpowered cohorts has limited research in this domain. Here, we prospectively enrolled a large cohort of 495 subjects with ALS (n=202) and FTD (n=168), or non-neurodegenerative controls (n=125). Based on cell-free plasma miRNA profiling by next generation sequencing and machine learning approaches, we develop nonlinear prediction models that accurately distinguish ALS and FTD from non-neurodegenerative controls in ~90% of cases. Among the miRNAs that contribute to classifying disease, we identified miRNAs shared between conditions as well as disease-specific miRNAs. The fascinating potential of diagnostic miRNA biomarkers might enable early-stage detection and a cost-effective screening approach for clinical trials that can facilitate drug development.

Introduction

15

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are 16 17 neurodegenerative diseases that reside along a clinico-pathological continuum (Ling et al, 2013; Majounie et al, 2012; Neumann et al, 2006; Renton et al, 2011; Strong et al, 2017; van Es et al, 18 19 2017). ALS is primarily a disease of the human motor neuron system, resulting in muscle 20 atrophy, paralysis and death (Al-Chalabi & Hardiman, 2013; Hardiman et al, 2011; Robberecht 21 & Philips, 2013), whereas FTD is characterized by frontal and temporal lobe atrophy, and 22 typically manifests with behavioral or language deficits (Strong et al., 2017). 23 Shared neuropathological inclusions of the RNA-binding proteins TAR DNA-binding protein 43 24 (TDP-43) (Neumann et al., 2006) and shared causative genes, chromosome 9 open reading 25 frame 72 (C9ORF72), TARDBP (TDP-43), VCP and TBK1 (Abramzon et al, 2020; Conforti et al, 26 2021), further resonate with comorbidity and clinical symptoms of both diseases in 10-20% of patients. Thus, one in five ALS patients meets the clinical criteria for a concomitant diagnosis of 27 28 FTD, and one in eight FTD patients is also diagnosed with ALS. However, there are also unique 29 mutations to each disease entity. For example, mutations in heterogeneous nuclear 30 ribonucleoprotein A1 (hnRNPA1) cause ALS, but not FTD (Andersen & Al-Chalabi, 2011; Chen 31 et al, 2013; Cirulli et al, 2015; Peters et al, 2015; Renton et al., 2011), and mutations in 32 progranulin (GRN), and charged multivesicular body protein 2B (CHMP2B) may cause FTD but 33 not ALS. 34 The diagnosis of ALS is currently based on medical history, clinical examination and exclusion 35 of mimicking disorders. Full-blown ALS is easily diagnosed by trained practitioners, however the 36 diagnostic process often takes 1-1.5 years, since progressive deterioration, indicating both 37 upper and lower motor neuron involvement, is required to define ALS. FTD can also be difficult 38 to diagnose, due to heterogeneity in clinical presentation (McKhann et al, 2001). Three main phenotypes of FTD are described: behavioral variant frontotemporal dementia (bvFTD). 39 40 characterized by changes in social behaviour and conduct, semantic dementia (SD), 41 characterized by the loss of semantic knowledge, leading to impaired word comprehension, and 42 progressive non-fluent aphasia (PNFA), characterized by progressive difficulties in speech 43 production (McKhann et al., 2001; Snowden et al, 2002). 44 Brain imaging and several biofluid proteins have been proposed as biomarkers for both ALS 45 and FTD (Al Shweiki et al, 2019; Ashton et al, 2021; Bellini et al, 2022; Benussi et al, 2019; Bian 46 et al, 2008; Borroni et al, 2015; Bourbouli et al, 2017; Bright et al, 2019; Chouliaras et al, 2022; 47 Das et al, 2022; Delaby et al, 2020; Eratne et al, 2022; Feneberg et al, 2018; Forgrave et al,

48 2019; Goncalves et al. 2017; Gonzalez-Garza et al. 2018; Hansson et al. 2019; Hu et al. 2013; 49 Jiskoot et al, 2019; Katisko et al, 2021; Katisko et al, 2020; Krishnan et al, 2022; McCarthy et al, 50 2018; Meeter et al, 2017; Meeter et al, 2018; Niikado et al, 2019; Oeckl et al, 2022; Prado et al, 51 2018; Rossi et al, 2018; Sheikh-Bahaei et al, 2017; Silva-Spinola et al, 2022; Teunissen et al, 52 2016; Thijssen et al, 2022; Turner et al, 2009; van der Ende et al, 2020; Verde et al, 2021; 53 Wilson et al, 2022; Xu et al, 2016). Among the proteins, noticeable are neurofilament light chain 54 (NfL), TDP-43 and, phospho-tau, amyloid beta and glial fibrillary acidic protein (GFAP). In this context, a recent study concluded that high NfL blood levels are indicative of the intensity of 55 56 neurodegeneration or the extent of the degenerated axons in both ALS and FTD (Ashton et al., 57 2021) but cannot contribute to the distinction between these two diseases. 58 miRNAs are a class of small, non-coding RNAs, that can be quantified in biofluids in a 59 massively parallel fashion, vielding fine-grained profiles (Coenen-Stass et al. 2018), miRNAs 60 play important roles in ALS pathogenesis and in motor neuron survival (Eitan & Hornstein, 2016; 61 Emde et al. 2015; Haramati et al. 2010; Reichenstein et al. 2019) and we have previously 62 shown the power of cell-free miRNAs as biomarkers in neurodegeneration (Magen et al, 2022; 63 Magen et al, 2021). Plasma miRNAs were also suggested as diagnostic biomarkers for ALS 64 (Banack et al, 2020; Benigni et al, 2016; Cloutier et al, 2015; de Andrade et al, 2016; Joilin et al, 65 2019; Ravnik-Glavač & Glavač, 2020; Ricci et al, 2018; Saucier et al, 2019; Sheinerman et al, 2017; Takahashi et al, 2015; Toivonen et al, 2014; Waller et al, 2017a; Wang & Zhang, 2020) or 66 67 FTD (Denk et al, 2018; Grasso et al, 2019; Kmetzsch et al, 2021; Muller et al, 2016; Piscopo et 68 al, 2018; Schneider et al, 2018; Sheinerman et al., 2017; Sproviero et al, 2021; Tan et al, 2021). 69 However, definitive markers have not been reported so far and initial biomarker studies were 70 confounded by cohort size, sample heterogeneity biased or pre-selection of candidate miRNA. 71 Furthermore, diagnosis of comorbid ALS-FTD patients with miRNAs has not been pursued. 72 In this study, we profiled blood plasma miRNAs (Coenen-Stass et al., 2018), in a cohort of 533 73 subjects and developed miRNA-based classifiers for diagnosing ALS and FTD. We 74 implemented ensemble machine learning approach, to address biomarker nonlinearity and were 75 able to expose unrevealed disease-associated signals. The diagnostic power of the study roots 76 from unbiased miRNA signature in a large and heterogeneous meta-cohort, and is validated in 77 an independent held-out cohort according to the TRIPOD guidelines (Collins et al., 2015). 78 Therefore, circulating miRNAs hold a fascinating potential as diagnostic biomarkers and as 79 means for patient stratification in clinical trials.

Results

We sought to determine the overall diagnostic capability of miRNA measurements in ALS and FTD. To this end, we based our study on analysis of plasma miRNA expression and the development of computational diagnostic models. The initial cohorts included a total of 533 participants, enrolled between 2009 and 2019, with clinical follow up time that ranged between 3 and 66 months. Summary of participants' basic characteristics are described in Table 1.

Quality control of data

We have performed next generation RNA sequencing for all samples and subjected miRNA data to quality control steps prior to prediction model development. We observed a younger mean age in both ALS controls (mean age 49.9±13, 95% CI [47.2-52.5]) and in FTD controls (mean age of 61±13, 95% CI [57-64]), whereas in other groups the mean age was around 65 (Figure S1). Since both ALS and FTD symptoms manifest late in life, with median disease onset at 55 and 58 years of age, respectively, we reduced age-variance by excluding 38 participants younger than 40, which reduced differences in mean age across the remaining meta-cohort of 495 subjects by 33%. Thus, 168 out of 169 FTD patients and 202 out of 206 patients with ALS were included in the analysis along with 125 out of 158 non-neurodegenerative control samples (Table S1). We then verified that a merged dataset of ALS and FTD controls, collected in two different clinical centers does not introduce biases, using Kullback–Leibler divergence measure and a t-distributed stochastic neighbor embedding (t-SNE) analysis (Figure S2A). This enabled analysis of all control data in a unified manner. ALS and FTD cases did not differ from the merged control group, or from each other (Figure S2B).

- 102 Out of the >2000 miRNA species that were aligned to the genome, only 132 fulfilled QC criteria.
- 103 Next, we quantified the differential miRNA levels in ALS, FTD and control samples (Figure 1A-
- 104 C), noting miRNAs that may distinguish ALS and FTD from control and from one another.

Development of binary classifiers for the diagnosis of ALS or FTD

We first established a baseline single-disease predictor for either ALS or FTD. A diagnostic prediction model for FTD was developed on a randomly selected training set of 135 FTD cases and 84 controls, comprising 75% of the total cohort (168 cases, 125 controls). As a replication cohort, the remaining 25% of the data were held out for model validation (33 FTD, 41 control samples).

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

The 132 miRNAs were tested as potential predictors, using an ensemble machine learning approach. miRNAs were ranked by their predictive value in the diagnosis of FTD, vs. individuals that did not suffer from neurodegeneration and considered healthy. For selecting the most predictive features during model development, we used Recursive Feature Elimination (RFE), an efficient approach that removes miRNAs (features) iteratively to identify those that contribute the most to prediction accuracy (Figure 2A). RFE obtained a set of 13 miRNAs with highest feature importance. The 13-miRNA-based predictor presented a mean receiver operating characteristic area under the curve (ROC AUC) of 0.9, by internal cross validation (Figure 2B). Furthermore, the 13-miRNA-based predictor was capable of predicting the diagnosis of FTD in an independent held-out (replication) cohort of 74 individuals with an ROC AUC of >0.9 (Figure 2C) and an average precision of 0.9. At a defined probability threshold (0.6), the classifier exhibits a 0.8 precision (PPV) with a 0.85 recall (sensitivity), a 0.87 specificity and a 0.2 false discovery rate values. The model is well calibrated and satisfactorily performs on held-out data (Figure 2D, E). Furthermore, a family of models trained with only a subset of the 13 most predictive features, displays a stable AUC ROC performance and reassures that the selected final features are suitable (Figure 2F). In summary, we determined 13 miRNAs that are able to call the diagnosis of FTD with high accuracy. We then sought to better understand the prediction model by investigating the relative effect of each individual miRNA. Therefore, we utilized post-hoc SHapley Additive exPlanations (SHAP) feature importance analysis to uncover the contribution of individual miRNAs to the FTD diagnostic predictor (Figure 3A, B). The key predictor revealed by SHAP is the astrocyte-derived exosomal miR-361 (Bu et al, 2020). Little is known about other miRNAs contributing to prediction. We further tested individual miRNAs as single predictors of FTD diagnosis. The ROC analysis revealed maximal AUC values of ~0.69 for miR-423-5p and miR-125b-5p (Table S2). In conclusion, 13 miRNAs are able to call the diagnosis of FTD with high accuracy. Similarly, an ALS-prediction model was developed by ensemble machine learning with RFE. using data from 149 ALS cases and 96 controls (training set). 53 ALS and 29 controls were held-out as an independent replication (validation) cohort. Following a computational RFE approach comparable to that developed for FTD (in Figure 2A), we depicted 12 miRNAs with the highest feature importance (Figure 4A). The predictor developed with these 12 miRNAs presented a mean ROC AUC of 0.86, by internal cross validation (Figure 4B). Furthermore, that 12-miRNA-based predictor was capable of predicting the diagnosis of ALS in an independent held-out (replication) cohort of 82 individuals with an ROC AUC of 0.78 (Figure 4C). The ALS model is sufficiently calibrated and a family of models, trained with only a subset of the 12 most predictive features, displays a stable AUC ROC performance (Figure 4 D-F). With a defined probability threshold set to 0.45, the classifier obtained a 0.81 precision (PPV) with a recall (sensitivity) of 0.98 over 0.94 specificity and a 0.19 false discovery rate.

SHAP feature importance analysis uncovered the contribution of miR-206 and miR-1-3p, two homologous muscle-expressed miRNAs, that were reported to increase in the blood of ALS patients (de Andrade *et al.*, 2016; Malacarne *et al.*, 2021; Raheja *et al.*, 2018; Tasca *et al.*, 2016; Waller *et al.*, 2017b). Likewise, miR-103a and miR-181b-5p are enriched in brain tissue and in spinal cord tissues (Ludwig *et al.*, 2016), and miR-181b-5p has been proposed as a prognostic marker for ALS (Magen *et al.*, 2021). In addition, we tested the diagnostic ability of each individual miRNAs as single predictors in terms of ROC AUC, which revealed predictive value at the range of 0.75 for miR-186-5p (maximal value) and down to 0.39 for miR-320a (minimal value, Table S3). We conclude that some individual miRNAs can be used on their own, however miRNA cooperative predictive value provides a superior performance (>0.78 vs. ~0.75 AUC ROC).

Development of multi-class predictor of ALS and FTD Diagnosis

Multi-disease classifiers may display improved performance by solving a single optimization problem, while exploiting a larger meta-cohort. Such classifiers can take into account the varying levels of relationships that may exist among the different disease entities. Additionally, a predictor that is potentially able to compare ALS and FTD may be informative about the molecular biomarker interpretation of the FTD-ALS continuum (ALS-FTD)(Strong *et al.*, 2017).

We established a meta-cohort composed of 495 subjects, with measurements of 132 miRNAs that passed QC. Then, we applied RFE on to the meta-cohort to reveal 16 miRNAs useful for creating a ternary classifier (ALS vs. FTD vs. healthy, Figure 6A). The multi-disease classifier achieved a weighted mean "one-vs-all" ROC AUC of 0.9 across all folds for all classes during training (Figure 6B) and a weighted "one-vs-all" AUC-ROC of 0.88 on untouched replication cohort (AUC ROC 0.76, 0.86, 0.97 for controls, ALS, FTD, respectively, Figure 6C). The model obtained sensitivity of 0.92/0.83, specificity of 0.95/0.79 and an NPV of 0.96/0.88 for FTD/ALS, respectively (Table 2). We also computed AUC ROC metric for one-vs-one classification,

175 according to the Hand & Till algorithm (Hand & Till, 2001): FTD vs controls 0.88, ALS vs 176 controls 0.74, FTD vs ALS 0.97. 177 In addition, we tested the performance of each of the 16 most predictive miRNAs as single 178 predictors (Table S4) and present the confusion matrices (Figure 6D, E). One miRNA, miR-185-179 5p, is used to predict both ALS and FTD (Figure 6F). Three other miRNAs, not selected in any 180 of the binary single-disease models, are exclusively selected in the multi-disease model (miR-24-3p, miR-148a-3p and miR-339-5p, Figure 6F). 182 SHAP feature importance analysis uncovered the contribution of individual miRNAs to the multi 183 disease predictor (Figure 7A, B, C). The most predictive miRNA, miR-1-3p, is shown to equally 184 influence predicting FTD and ALS, while having only a minor contribution in predicting 'controls' 185 class (Figure 7B,C). miR-206, which is a muscular miRNA like miR-1-3p, is the most predictive 186 in ALS, with almost no predictive capacity in the FTD model. Similarly, miR-361 mostly contribute to risk of FTD. This suggests shared miRNAs that are robust features that may be 188 biologically relevant to the ALS-FTD continuum. 189 Finally, we tested whether miRNA plasma miRNA classifiers reported in previous works 190 (Kmetzsch et al., 2021; Sheinerman et al., 2017) perform equally to, better or worse than our classifiers in the training and held out datasets. Combination of miR-34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p, selected previously (Kmetzsch et al., 2021), was consistently inferior 193 to our classifiers in distinguishing between FTD and controls, ALS and controls, and FTD and ALS, with lower AUC values (Figure 8). Similarly, the classifiers selected in Sheinerman et al., 195 2017 (42) were inferior to our panels of miRNA classifiers. Thus, when tested in comparison to 196 reported miRNA classifiers from the literature, our panels of miRNA classifiers perform better, 197 with AUC values ≥0.78 and in some cases exceeding 0.9. 198 In summary, we have shown that a panel of <16 miRNAs can distinguish between patients with 199 ALS or FTD and non-degeneration controls, as well as between ALS, FTD and controls, in a 200 multiclass model.

181

187

191

192

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

Discussion The need to facilitate the diagnosis of neurodegeneration, in early disease stages and in the face of clinical heterogeneity, raises the hope for new effective biomarkers for ALS and FTD. Biomarkers may further inform about the comorbidity risk within the ALS-FTD continuum (Strong et al., 2017) Circulating miRNAs hold a fascinating potential as diagnostic biomarkers that were not fully addressed to date. By using a large cohort of 495 subjects, an unbiased, next generation sequencing approach and advanced computational methods, we overcome limitations of past works in developing biomarkers for neurodegeneration. First, we overcome the specificity problem recently reported for NfL. Since NfL levels are high in many neurodegenerative states, it cannot distinguish ALS from FTD (Ashton et al., 2021). In addition, within miRNA biomarker development, our binary classifiers are more precise than published predictors (Kmetzsch et al., 2021; Sheinerman et al., 2017). In addition, we develop a multi-disease miRNA predictor model for ALS and FTD. The use of gradient boosting trees, an ensemble learning approach, allows discovering miRNAs that are in a nonlinear relationship with the disease status. Machine-learning classifiers gain affirmation by cross validation in the training dataset. Furthermore, our models are externally validated on held-out data, which was not used during feature selection and model development, according to the TRIPOD guidelines (Collins et al., 2015). The multi-disease model learns about related (but different) diagnostic tasks, and jointly selects features for all tasks. This way sample size is increased, features-to-sample ratio of the data is reduced and yet the particularities of each data set are kept (Azencott, 2020). In the selection of features, the multi-disease model is intentionally optimized to separate between ALS and FTD by penalizing for features that enhance disease misclassification and prioritizing miRNAs that are differentially measured. This is deciphered when the relative contribution of individual features to the predictive model unfolds by SHAP analysis (Lundberg et al, 2020). We revealed that 16 miRNAs are able to classify FTD, ALS or healthy controls, most of which are disease-specific (e.g., miR-206 for ALS and miR-361 for FTD). Interestingly, the most predictive miRNAs are abundant in the neuromuscular and immune systems, which is conceivable, as neuronal loss, muscle atrophy and neuro-inflammation, come into play in these pathologies.

232 According to the human miRNA tissue atlas (Ludwig et al., 2016), most of the selected miRNAs 233 are CNS-enriched (let-7c-5p/7i-5p, miR-23b-3p, miR-26a-5p, miR-103a-3p, miR-107, miR-125b-234 5p, miR-148a-3p, miR-181b-5p, miR-185-5p, miR-320a, miR-339-5p, miR-379 and miR-484), or 235 muscle-enriched (miR-1-3p, miR-26a-5p, and miR-206). 236 miR-26a, miR-326, miR-484 and miR-361 were associated with FTD diagnosis in our data and 237 with cognitive deficits or Alzheimer's disease (AD) in other analyses (Allach El Khattabi et al, 238 2020; Chang et al, 2017; Cogswell et al, 2008; Goncalves et al, 2019; He et al, 2020; Ludwig et 239 al, 2019; Wingo et al, 2020). In mice, miR-326 inhibited tau phosphorylation, a hallmark of FTD 240 (He et al., 2020). Interestingly, miR-326, miR-484 and miR-361 contributed to FTD diagnosis 241 more than to ALS diagnosis. 242 miR-23b improved cognitive impairments in a rat model of traumatic brain injury (Sun et al, 243 2018) and alleviated neuronal apoptosis (Chen et al, 2014). Brain-enriched miR-107 was 244 selected as predictor in the FTD model and in the multi-disease model, and was also implicated 245 in AD (Muller et al. 2014; Nelson & Wang, 2010; Prendecki et al. 2019; Wang et al. 2020; Wang 246 et al, 2008; Yilmaz et al, 2016). 247 miR-206 and miR-1-3p are muscle-derived miRNAs, that were shown to increase in the blood of 248 ALS patients (de Andrade et al., 2016; Malacarne et al., 2021; Raheja et al., 2018; Tasca et al., 249 2016; Waller et al., 2017b), presumably as a result of muscle tissue breakdown. Accordingly, 250 both miRNAs were selected as predictive features in the ALS and multiclass models but not the 251 FTD model. However, when breaking out the contribution of these two miRNAs to the diagnosis 252 of ALS, FTD and controls, miR-206 specifically contributes to the diagnosis of ALS, but not of 253 FTD, while the plasma levels of miR-1-3p contribute to prediction of both diseases in the 254 multiclass model. According to the SHAP analysis, it seems that low levels of miR-1-3p 255 contribute to the diagnosis of FTD plausibly by distinguishing it from high levels of miR-1-3p in 256 ALS. 257 Let-7c and miR-326 are associated with suppression of neuroinflammation (Ni et al., 2015; Zhao 258 et al, 2019). Changes in blood levels of miR-326, miR-26a, and miR-629 are associated with 259 multiple sclerosis (MS), a disease that results from autoimmune neuroinflammation, (Baulina et 260 al. 2018: Dolati et al. 2018: Honardoost et al. 2014: Lindberg et al. 2010: Niwald et al. 2017: 261 Regev et al, 2018; Sharaf-Eldin et al, 2017; Yang et al, 2014). Moreover, serum miR-629 was 262 negatively correlated with MS patient brain volume and lesion severity, respectively (Regev et 263 al, 2017). Thus, some of our miRNA predictors are associated directly or indirectly with 264 neuroinflammation, a process which occurs in both FTD and ALS.

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

associated signals.

We would like to put forward a few notable limitations: as is the case with machine learning, the study is limited in providing mechanistic insight for the measured changes in cell-free miRNA levels and why defined nonlinear patterns are strongly predictive of disease states. Discrepancies from conclusions of past studies (Denk et al., 2018; Grasso et al., 2019; Kmetzsch et al., 2021; Piscopo et al., 2018; Sheinerman et al., 2017) are plausibly related to the progress we present in power (larger cohort) and to our unbiased analysis that contrasts past biased choice of miRNA candidates. While we kept held-out cohort for external validation, towards clinical diagnostic usage, it is warranted to test the predictor on an independent cohort of different ethnicity. In addition, the documentation of FTD patients with neuromuscular symptoms and of ALS patients with behavioral symptoms is limited and reduced our ability to investigate the full range of information at the ALS-FTD continuum. In summary, we have found specific molecular miRNA patterns that can contribute to diagnosis of FTD and ALS. These patterns are further alluding to differences and commonalities in the underlying molecular changes in the ALS - FTD continuum. Therefore, the work encourages testing if circulating miRNAs biomarkers can be used as a cost-effective screening approach to increase speed or precision in the diagnosis of suspected neurodegenerative states, thereby allowing early-stage detection of high-risk individuals prior to inclusion in prospective clinical trials. More broadly, the findings demonstrate the importance of integrating machine learning into clinical biomarker studies, addressing nonlinearity and exposing otherwise cryptic disease-

286

287

288

289

290

291292

293

294

295

296

297

298

299

300

301

302

303 304

305

306

307

308

309

310

311

312

313

314

315

316

317

Methods Standard protocol approvals, registrations, and patient consents Approvals were obtained from the local research ethics committee and all participants provided written consent (or gave verbal permission for a carer to sign on their behalf). For ALS samples, recruitment, sampling procedures and data collection have been performed according to Protocol (Protocol number 001, version 5.0 Final – 30th November 2015). Participants and Sampling Demographic data of study participants are detailed in Table 1. ALS samples and their respective healthy controls (N = 206 and 102, respectively) were obtained from the ALS biomarker study. ALS patients were diagnosed according to standard criteria by experienced ALS neurologists. Healthy controls were typically spouses or relatives of patients. FTD subjects and their respective controls were enrolled in the longitudinal FTD cohort studies at UCL. Study cohort included 169 FTD patients and 56 healthy controls. Blood was collected by venipuncture in EDTA tubes, and plasma was recovered from the whole blood sample by centrifugation and stored at -80°C until RNA extraction subsequent small RNA next generation sequencing. Frozen plasma samples of ALS, FTD and controls from the UCL Biobanks were shipped to the Weizmann Institute of Science for molecular analysis. Study Design We determined the sample size by the following power analysis: 150 controls and 150 cases (either ALS or FTD) are required to obtain an ROC AUC of 0.7 with a power of 99% and a pvalue of 0.0001. Phenotypic data on de-identified patients was separated and blinded during steps of the molecular analysis. Small RNA Next Generation Sequencing Total RNA was extracted from plasma using the miRNeasy micro kit (Qiagen, Hilden, Germany) and quantified with Qubit fluorometer using RNA broad range (BR) assay kit (Thermo Fisher Scientific, Waltham, MA), For small RNA next generation sequencing (RNA-seg), libraries were prepared from 7.5 ng of total RNA using the QIAseg miRNA Library Kit and QIAseg miRNA NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of samples. Samples were randomly allocated to library preparation and sequencing in batches. Precise linear quantification of miRNA is achieved by using unique molecular identifiers (UMIs), of random 12-nucleotide after 3' and 5' adapter ligation, within the reverse transcription primers

(Coenen-Stass *et al.*, 2018). cDNA libraries were amplified by PCR for 22 cycles, with a 3' primer that includes a 6-nucleotide unique index, followed by on-bead size selection and cleaning. Library concentration was determined with Qubit fluorometer (dsDNA high sensitivity assay kit; Thermo Fisher Scientific, Waltham, MA) and library size with Tapestation D1000 (Agilent). Libraries with different indices were multiplexed and sequenced on NextSeq 500/550 v2 flow cell or Novaseq SP100 (Illumina), with 75bp single read and 6bp index read. Fastq files were de-multiplexed using the user-friendly transcriptome analysis pipeline (UTAP) (Kohen *et al*, 2019). Human miRNAs, as defined by miRBase (Kozomara & Griffiths-Jones, 2014), were mapped using the GeneGlobe pipeline (https://geneglobe.qiagen.com/us/analyze). Sequencing data were normalized with DESeq2 package (Love *et al*, 2014) under the assumption that miRNA counts followed negative binomial distribution and data were corrected for the library preparation batch in order to reduce its potential bias.

Constructing Cohorts and Biases Associated with the Data-gathering Process

Each disease cohort has been utilized for building and validating a single-disease (binary) classifier that can be used as an applicative predictor for clinicians. Then, a meta-cohort, a unified case-control cohort for both ALS and FTD disease, was constructed to be used for development and assessment of a multi-disease risk prediction model. As our dataset is observational and generated by fusion of few study cohorts, we particularly considered bias associated with the data-gathering process. First, we verified that the control cohorts are not coming from an underlying different population using t-SNE analysis following batch correction and DESeq2 normalization. We then performed QC on the age distribution of subjects and thereby excluded 38 participants younger than 40, to reduce differences in mean age across the different cohorts. A higher prevalence of males among ALS patients (59%, vs. 31 % in controls) was observed. This reflects the higher prevalence of ALS in males than in females, as reported previously (Collaborators, 2018). Therefore, to eliminate the confounding effect, resulting from statistical relationship between sex and ALS status, the sex variable was removed from the list of candidate predictors. A higher prevalence of males among FTD patients (65%) than among the controls (31%) was observed as well. Hence, sex was removed from the list of candidate predictors to eliminate confounding biases.

Verifying de-separation of non-degeneration control cohorts

We established a cohort of 158 non-neurodegenerative controls. Since they originated from two repositories, Queen Mary hospital (N=102) and University College London from (N=56), we first

verified that the two sets (distributions) can be considered together and that they do not impose biases, based on the biorepository from which they were collected. Non-neurodegenerative controls from Queen Mary hospital are presented in light blue (ALS), while controls from University College London are presented in red. The t-distributed stochastic neighbor embedding (t-SNE) analysis reveals that both control distributions could have been sampled from a single population (Figure S1). The Kullback–Leibler divergence, a measure of difference between probability distributions, indicating a small difference between the two sets in question (KL = 0.283). Therefore, control samples were unified and considered as a single meta-cohort for analysis of miRNA abundance, without introducing additional sampling biases.

Gradient Boosted Trees for the Development of Disease Binary Classifiers

The ALS-disease binary classifier and FTD-disease binary classifier were developed using Gradient Boosting Classifier, a machine learning algorithm that uses a gradient boosting framework.

Diagnostic models were developed, validated and reported according to the TRIPOD guidelines (Collins et al., 2015) (https://www.tripod-statement.org/). Gradient Boosting trees (Elith et al., 2008; Witten et al, 2017), a decision-tree-based ensemble model, differ fundamentally from conventional statistical techniques that aim to fit a single model using the entire dataset. Such ensemble approach improves performance by combining strengths of models that learn the data by recursive binary splits, such as trees, and of "boosting", an adaptive method for combining several simple (base) models. At each iteration of the gradient boosting algorithm, a subsample of the training data is selected at random (without replacement) from the entire training data set, and then a simple base learner is fitted on each subsample. The final boosted trees model is an additive tree model, constructed by sequentially fitting such base learners on different subsamples. This procedure incorporates randomization, which is known to substantially improve the predictor accuracy and also increase robustness. Additionally, boosted trees can fit complex nonlinear relationships, and automatically handle interaction effects between predictors as addition to other advantages of tree-based methods, such as handling features of different types and accommodating missing data. Hence, in many cases their predictive performance is superior to most traditional modelling methods.

Additional gain of these algorithms is the various loss functions that can be applied, both for binary and multi-class problems. Using the softmax loss function, we explicitly estimated the

386

387

388

389

390

391

392393

394

395

396

397

398399

400

401 402

403

404

405

class conditional probabilities, which allow us to demonstrate the performance of each of the classifiers both as "soft-classifiers" (i.e., predicting class probabilities) and "hard-classifiers" (i.e., setting a probability threshold and predicting a class). The former approximates a continuous number as output - the class conditional probabilities - and then performs classification based on these estimated probabilities. In contrast, hard classifiers output a discrete number as the decision - directly targeting the classification decision boundary, without producing the probability estimation. A gradient boosting classifier was developed with a feature set of 132 miRNA predictors, age and sex. Dataset was partitioned to training-set (75%) and validation-set (25%) which was used as held-out data. The training-set was cross-validated during training with stratified 3-fold cross validation. An ROC was generated for each of the folds and individual and mean AUCs were calculated along with 95% confidence intervals. The chosen hyperparams in ALS-disease classifier: gamma=0.1, learning rate=0.1, max_depth=3, n_estimators=120, subsample=0.9 and tol=0.01. The chosen hyperparams in FTD-disease classifier: ccp_alpha=0.0, learning_rate=0.5, max depth=8, max features=0.45, min samples leaf=14, min samples split=8,, n_estimators=100, subsample=0.45 and tol=0.0001.

Gradient Boosted Trees for Multi-class Prediction with "one-vs-the-rest" Strategy

406

407

408

409

410

411

412

413

414

415

416

417 418

419

420

421 422

423

424425

426

427

428

429

430

431

432

433 434

435

436

437

438 439 A Gradient Boosting multi-class classifier was implemented with "one-vs-all" (or one-vs-the-rest) strategy for diagnostic prediction between ALS diseased, FTD diseased and control subjects. Performance of a multi-class model is visualized by plotting the performance of 3 binary classifiers, "One-vs-rest" strategy involves fitting a single classifier per class, with the samples of that class considered as positive samples, and all other samples as negatives. A soft-classifier with "one-vs-rest" strategy outputs 3 probabilities for each subject in the data, where a good classifier should assign a high probability to the correct class, while assigning low probabilities for XGBClassifier: the other classes. Hyperparams objective='multi:softprob', booster='abtree'. gamma=0.01, learning rate=0.5, max depth=3. n estimators=120, subsample=0.9 and tol=0.01.

Dataset was partitioned to training-set (75%, stratified 3-fold cross validation) and validation-set (25%) which was used as held-out data. An ROC was generated for each of the folds and individual and mean AUCs were calculated along with 95% confidence intervals. The area under the ROC curve is a natural measure of separability between the 3 estimated probability distributions and possesses the singular merit that it is independent of costs, priors, or (consequently) any classification threshold(Hand & Till, 2001).

Predictor Selection by Recursive Feature Elimination (RFE)

For selecting the most predictive features during prediction model development, we used *Recursive Feature Elimination* (RFE) algorithm, an efficient recursive approach for eliminating features from a training dataset with K-fold cross validation. RFE works by iteratively removing features and using model accuracy to identify which features contribute the most to prediction. Tree-based importance scores of 132 miRNAs were used here in order to rank features, and thus reduce the dimension of miRNA measurements needed for prediction by ~90% (12-16 features in a model in total).

RFE was implemented with Extra Trees Classifier and the following hyperparms: criterion="entropy", max_features=0.9, n_estimators=10. The performance scorer used to optimize selection: ROC AUC score in single disease models and weighted ROC AUC score in the multi-disease model.

Feature Importance and SHAP Analysis

Although gradient boosting tree models are complex models, they can automatically provide an approximation of feature importance from the trained boosted trees. A miRNA predictor is assigned with an importance score in every single tree, where the Gini purity index is used to assess split points in the tree. The score of a feature is calculated based on the amount of improvement in the Gini index achieved by split points that include the feature, weighted by the number of observations in that node. The final importance score of a feature is calculated by an average across all decision trees within the final model.

- For local interpretability of the predictive model, we used SHapley Additive exPlanations (SHAP) (Lundberg *et al.*, 2020), the current state of the art in Machine Learning explainability tools. Giving the smallest set of features that reduced the loss function the most (by XGBoost feature importance), SHAP provides estimates and visualizations to infer what decisions the model is making. This is achieved by quantifying the contribution that each feature brings to each prediction made by the model.
- Appendix

440

441

442

443

444 445

446

447

448449

450

451

452

453

454

455 456

464 465

471472473

- 457 IDs of 38 subjects removed due to age-based QC:
- 458 'CTRL rep9', 'CTRL rep10', 'CTRL rep13', 'CTRL rep19', 'CTRL rep16',
- 459 'CTRL_rep18', 'CTRL_rep20', 'FTD30', 'CTRL_rep17', 'CTRL12', 'CTRL13',
- 460 'CTRL2', 'CTRL5', 'CTRL56', 'CTRL57', 'CTRL58', 'CTRL68', 'CTRL100',
- 461 'CTRL111', 'CTRL20', 'CTRL22', 'CTRL23', 'CTRL24', 'CTRL27', 'CTRL29',
- 462 'CTRL33', 'CTRL48', 'CTRL50', 'CTRL54', 'CTRL60', 'CTRL62', 'CTRL73',
- 463 'CTRL82', 'CTRL83', 'FA42', 'SA22', 'BUH00025', 'UCH00019'

Acknowledgments

- We thank Vittoria Lombardi (UCL) for technical assistance. We acknowledge patients with FTD,
- 467 ALS, MS and healthy volunteers for their contribution and ALS biomarkers study co-workers for
- 468 biobanking, which has made this study possible (REC 09/H0703/27). We also thank the North
- 469 Thames Local Research Network (LCRN) for its support. EH is the Mondry Family Professorial
- 470 Chair and Head of the Nella and Leon Benoziyo Center for Neurological Diseases.

Funding

474

475

476

477

478

479

480

481

482

483

484

485 486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

Research at the Hornstein laboratory is supported by the CReATe consortium and ALSA (program: "Prognostic Value of miRNAs in Biofluids From ALS Patients"), the RADALA Foundation; AFM Telethon (20576); the Weizmann-Brazil Center for Research on Neurodegeneration at Weizmann Institute of Science; the Minerva Foundation, with funding from the Federal German Ministry for Education and Research; the ISF Legacy Heritage Fund (828/17); the Israel Science Foundation (135/16, 3497/21, 424/22, 425/22); United States -Israel Binational Science Foundation (#2021181); A research grant from the Anita James Rosen Foundation; Target ALS (118945); the Thierry Latran Foundation for ALS Research; the European Research Council under the European Union's Seventh Framework Program ([FP7/2007–2013]/ERC grant agreement number 617351); ERA-Net for Research Programs on Rare Diseases (eRARE FP7) via the Israel Ministry of Health; Dr Sydney Brenner and friends; Edward and Janie Moravitz; A. Alfred Taubman through IsrALS; Yeda-Sela; Yeda-CEO; the Israel Ministry of Trade and Industry; the Y. Leon Benoziyo Institute for Molecular Medicine; the Nella and Leon Benoziyo Center for Neurological Disease; the Kekst Family Institute for Medical Genetics; the David and Fela Shapell Family Center for Genetic Disorders Research; the Crown Human Genome Center: the Nathan, Shirley, Philip, and Charlene Vener New Scientist Fund: the Julius and Ray Charlestein Foundation; the Fraida Foundation; the Wolfson Family Charitable Trust; the Adelis Foundation; Merck (UK); M. Halphen; the estates of F. Sherr, L. Asseof, and L. Fulop; the Goldhirsh-Yellin Foundation; the Redhill Foundation-Sam and Jean Rothberg Charitable Trust; Dr. Dvora and Haim Teitelbaum Endowment Fund; A research grant from the Anita James Rosen Foundation. The ALS-Therapy Alliance, Motor Neuron Disease Association (UK); this work was supported by the Motor Neuron Disease Association (MNDA) 839-791. The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research Trust, and The Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as well as an Alzheimer's Society grant (AS-PG-16-007). JDR is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). PF is supported by a Medical Research Council Senior Clinical Fellowship, an MRC/MND LEW Fellowship, the NIHR UCLH BRC and the Lady Edith Wolfson Fellowship scheme (MR/M008606/1 and MR/S006508/1).

508 NSY was supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data 509 Science Research Center, by a research grant from the Estate of Tully and Michele Plesser and 510 by Maccabim Foundation. I.M. was supported by Teva Pharmaceutical Industries as part of the 511 Israeli National Network of Excellence in Neuroscience (fellowship no. 117941). 512 513 **Authors' contribution** 514 I.M., P.F., J.D.R. and E.H. conceived research. 515 I.M., N.S.Y. and E.H. analyzed the data. 516 A.M. and J.D.R. established cohort, gained ethical approval and collected human samples for 517 research. 518 Y.B., C.H. and I.S. assisted research. 519 I.M., N.S.Y., P.F., A.M., J.D.R. and E.H. wrote the manuscript, with comments and final 520 approval by all other authors. 521 J.D.W. provided resources for research and input in research development. 522 A.M. and J.D.R. are corresponding authors for cohorts and clinical data. P.F. and E.H. are 523 corresponding authors for all other facets of the work. 524 525 Conflicts of interests

The authors state that they have no conflicts of interests.

References

- 528 Abramzon YA, Fratta P, Traynor BJ, Chia R (2020) The Overlapping Genetics of Amyotrophic
- 529 Lateral Sclerosis and Frontotemporal Dementia. Front Neurosci 14: 42
- Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment
- 531 and time. *Nat Rev Neurol* 9: 617-628
- 532 Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, Diehl-Schmid J,
- 533 Jahn H, Anderl-Straub S, Ludolph AC et al (2019) Neurofilament light chain as a blood
- 534 biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal
- 535 dementia. *J Psychiatr Res* 113: 137-140
- 536 Allach El Khattabi L, Heide S, Caberg J-H, Andrieux J, Doco Fenzy M, Vincent-Delorme C,
- 537 Callier P, Chantot-Bastaraud S, Afenjar A, Boute-Benejean O et al (2020) 16p13.11
- 538 microduplication in 45 new patients: refined clinical significance and genotype-phenotype
- correlations. *Journal of Medical Genetics* 57: 301-307
- Andersen PM, Al-Chalabi A (2011) Clinical genetics of amyotrophic lateral sclerosis: what do we
- really know? *Nat Rev Neurol* 7: 603-615
- 542 Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL,
- Pascoal TA, Lleo A, Parnetti L *et al* (2021) A multicentre validation study of the diagnostic value
- of plasma neurofilament light. *Nat Commun* 12: 3400
- 545 Azencott C-A, 2020. Machine learning tools for biomarker discovery. Sorbonne Université,
- 546 UPMC.
- 547 Banack SA, Dunlop RA, Cox PA (2020) An miRNA fingerprint using neural-enriched
- 548 extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral
- 549 sclerosis/motor neuron disease. Open Biol 10: 200116
- Baulina N, Kulakova O, Kiselev I, Osmak G, Popova E, Boyko A, Favorova O (2018) Immune-
- related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple
- sclerosis relapse and remission. *J Neuroimmunol* 317: 67-76
- Bellini S, Saraceno C, Benussi L, Squitti R, Cimini S, Ricci M, Canafoglia L, Coppola C, Puoti G,
- 554 Ferrari C et al (2022) Plasma Small Extracellular Vesicles with Complement Alterations in
- 555 GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. Cells 11
- 556 Benigni M, Ricci C, Jones AR, Giannini F, Al-Chalabi A, Battistini S (2016) Identification of
- 557 miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis
- 558 patients. Neuromolecular medicine 18: 551-560
- Benussi A, Gazzina S, Premi E, Cosseddu M, Archetti S, Dell'Era V, Cantoni V, Cotelli MS,
- Alberici A, Micheli A et al (2019) Clinical and biomarker changes in presymptomatic genetic
- frontotemporal dementia. *Neurobiol Aging* 76: 133-140
- Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark
- 563 CM, Rosso S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known
- 564 pathology. *Neurology* 70: 1827-1835
- Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, Sorbi S, Scarpini E,
- 566 Padovani A (2015) Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal
- 567 dementia. Amyotroph Lateral Scler Frontotemporal Degener 16: 86-91
- 568 Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, Zaganas I, Evdokimidis I,
- 569 Kapaki E, Paraskevas GP (2017) Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined
- 570 with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and
- 571 Frontotemporal Dementia Spectrum Disorders. Dement Geriatr Cogn Disord 44: 144-152
- 572 Bright F, Werry EL, Dobson-Stone C, Piguet O, Ittner LM, Halliday GM, Hodges JR, Kiernan
- 573 MC, Loy CT, Kassiou M et al (2019) Neuroinflammation in frontotemporal dementia. Nature
- 574 Reviews Neurology 15: 540-555

- 575 Bu X, Li D, Wang F, Sun Q, Zhang Z (2020) Protective Role of Astrocyte-Derived Exosomal
- 576 microRNA-361 in Cerebral Ischemic-Reperfusion Injury by Regulating the AMPK/mTOR
- 577 Signaling Pathway and Targeting CTSB. Neuropsychiatr Dis Treat 16: 1863-1877
- 578 Chang WS, Wang YH, Zhu XT, Wu CJ (2017) Genome-Wide Profiling of miRNA and mRNA
- 579 Expression in Alzheimer's Disease. *Med Sci Monit* 23: 2721-2731
- 580 Chen Q, Xu J, Li L, Li H, Mao S, Zhang F, Zen K, Zhang CY, Zhang Q (2014) MicroRNA-23a/b
- 581 and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal
- 582 apoptosis. Cell Death Dis 5: e1132
- 583 Chen S, Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update.
- 584 Mol Neurodegener 8: 28
- Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-Sedano
- 586 MA, Heslegrave AJ, Zetterberg H et al (2022) Differential levels of plasma biomarkers of
- 587 neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and
- 588 progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 93: 651-658
- 589 Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF,
- Wang Q, Krueger BJ et al (2015) Exome sequencing in amyotrophic lateral sclerosis identifies
- risk genes and pathways. Science 347: 1436-1441
- 592 Cloutier F, Marrero A, O'Connell C (2015) MicroRNAs as potential circulating biomarkers for
- 593 amyotrophic lateral sclerosis. *Journal of Molecular Neuroscience* 56: 102-112
- 594 Coenen-Stass AML, Magen I, Brooks T, Ben-Dov IZ, Greensmith L, Hornstein E, Fratta P
- 595 (2018) Evaluation of methodologies for microRNA biomarker detection by next generation
- 596 sequencing. *RNA Biol* 15: 1133-1145
- Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown
- 598 D, Chen C et al (2008) Identification of miRNA changes in Alzheimer's disease brain and CSF
- 599 yields putative biomarkers and insights into disease pathways. *J Alzheimers Dis* 14: 27-41
- 600 Collaborators GBDMND (2018) Global, regional, and national burden of motor neuron diseases
- 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*
- 602 17: 1083-1097
- 603 Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent Reporting of a multivariable
- prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann
- 605 Intern Med 162: 55-63
- 606 Conforti FL, Renton AE, Houlden H (2021) Editorial: Multifaceted Genes in Amyotrophic Lateral
- 607 Sclerosis-Frontotemporal Dementia. *Front Neurosci* 15: 680185
- Das S, Dewit N, Jacobs D, Pijnenburg YAL, In 't Veld S, Coppens S, Quaglia M, Hirtz C,
- 609 Teunissen CE, Vanmechelen E (2022) A Novel Neurofilament Light Chain ELISA Validated in
- Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline,
- and the Evaluation of Candidate Proteins for Immunoassay Calibration. Int J Mol Sci 23
- de Andrade HM, de Albuquerque M, Avansini SH, de SRC, Dogini DB, Nucci A, Carvalho B,
- 613 Lopes-Cendes I, Franca MC, Jr. (2016) MicroRNAs-424 and 206 are potential prognostic
- 614 markers in spinal onset amyotrophic lateral sclerosis. J Neurol Sci 368: 19-24
- 615 Delaby C. Alcolea D. Carmona-Iraqui M. Illan-Gala I. Morenas-Rodriguez E. Barroeta I. Altuna
- 616 M, Estelles T, Santos-Santos M, Turon-Sans J et al (2020) Differential levels of Neurofilament
- 617 Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders.
- 618 Sci Rep 10: 9161
- Denk J, Oberhauser F, Kornhuber J, Wiltfang J, Fassbender K, Schroeter ML, Volk AE, Diehl-
- 620 Schmid J, Prudlo J, Danek A et al (2018) Specific serum and CSF microRNA profiles distinguish
- sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and
- 622 cognitively healthy controls. *PLoS One* 13: e0197329
- 623 Dolati S, Aghebati-Maleki L, Ahmadi M, Marofi F, Babaloo Z, Ayramloo H, Jafarisavari Z,
- 624 Oskouei H, Afkham A, Younesi V et al (2018) Nanocurcumin restores aberrant miRNA

- expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial. *J Cell*
- 626 Physiol 233: 5222-5230
- 627 Eitan C, Hornstein E (2016) Vulnerability of microRNA biogenesis in FTD-ALS. *Brain Res*
- 628 Elith J, Leathwick JR, Hastie T (2008) A working guide to boosted regression trees. *J Anim Ecol*
- 629 77: 802-813
- 630 Emde A, Eitan C, Liou LL, Libby RT, Rivkin N, Magen I, Reichenstein I, Oppenheim H, Eilam R,
- 631 Silvestroni A et al (2015) Dysregulated miRNA biogenesis downstream of cellular stress and
- 632 ALS-causing mutations: a new mechanism for ALS. EMBO J 34: 2633-2651
- 633 Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, Janelidze S, Cadwallader C,
- Walia N, Ney B et al (2022) Cerebrospinal fluid neurofilament light chain differentiates primary
- psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders
- 636 in clinical settings. *Alzheimers Dement*
- 637 Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR (2018) Towards a TDP-43-Based
- 638 Biomarker for ALS and FTLD. Mol Neurobiol 55: 7789-7801
- Forgrave LM, Ma M, Best JR, DeMarco ML (2019) The diagnostic performance of neurofilament
- light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic
- lateral sclerosis: A systematic review and meta-analysis. Alzheimers Dement (Amst) 11: 730-
- 642 743
- Goncalves M, De Carvalho M, Peixoto C, Alves P, Barreto C, Oliva A, Pinto S, Laborinho-
- Pronto A, Gromicho M, Costa J (2017) Phosphoneurofilament heavy chain and vascular
- endothelial growth factor as cerebrospinal fluid biomarkers for ALS. Amyotroph Lateral Scler
- 646 Frontotemporal Degener 18: 134-136
- Goncalves TF, Piergiorge RM, Dos Santos JM, Gusmao J, Pimentel MMG, Santos-Reboucas
- 648 CB (2019) Network Profiling of Brain-Expressed X-Chromosomal MicroRNA Genes Implicates
- Shared Key MicroRNAs in Intellectual Disability. *J Mol Neurosci* 67: 295-304
- 650 Gonzalez-Garza MT, Martinez HR, Cruz-Vega DE, Hernandez-Torre M, Moreno-Cuevas JE
- 651 (2018) Adipsin, MIP-1b, and IL-8 as CSF Biomarker Panels for ALS Diagnosis. *Dis Markers*
- 652 2018: 3023826
- 653 Grasso M, Piscopo P, Talarico G, Ricci L, Crestini A, Tosto G, Gasparini M, Bruno G, Denti MA,
- 654 Confaloni A (2019) Plasma microRNA profiling distinguishes patients with frontotemporal
- 655 dementia from healthy subjects. Neurobiol Aging
- 656 Hand DJ, Till RJ (2001) A simple generalisation of the area under the ROC curve for multiple
- class classification problems. *Machine learning* 45: 171-186
- Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldo M, Nilsson C, Blennow K, van
- Swieten JC, Janelidze S (2019) CSF placental growth factor a novel candidate biomarker of
- 660 frontotemporal dementia. *Ann Clin Transl Neurol* 6: 863-872
- Haramati S, Chapnik E, Sztainberg Y, Eilam R, Zwang R, Gershoni N, McGlinn E, Heiser PW,
- Wills AM, Wirguin I et al (2010) miRNA malfunction causes spinal motor neuron disease. Proc
- 663 Natl Acad Sci U S A 107: 13111-13116
- 664 Hardiman O, van den Berg LH, Kiernan MC (2011) Clinical diagnosis and management of
- amyotrophic lateral sclerosis. Nat Rev Neurol 7: 639-649
- He B, Chen W, Zeng J, Tong W, Zheng P (2020) MicroRNA-326 decreases tau phosphorylation
- and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in
- 668 Alzheimer's disease. J Cell Physiol 235: 480-493
- Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M (2014) miR-326 and miR-
- 670 26a, two potential markers for diagnosis of relapse and remission phases in patient with
- 671 relapsing-remitting multiple sclerosis. *Gene* 544: 128-133
- 672 Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, Shelnutt M, Van Deerlin V,
- 673 Trojanowski JQ, Levey AI (2013) Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-
- 674 TDP. Neurology 81: 1945-1952

- Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S, van der Ende EL,
- 676 van Minkelen R, Rombouts S, Papma JM et al (2019) Longitudinal multimodal MRI as
- prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. *Brain*
- 678 142: 193-208
- Joilin G, Leigh PN, Newbury SF, Hafezparast M (2019) An overview of microRNAs as
- 680 biomarkers of ALS. Frontiers in neurology 10: 186
- 681 Katisko K, Cajanus A, Huber N, Jaaskelainen O, Kokkola T, Karkkainen V, Rostalski H,
- Hartikainen P, Koivisto AM, Hannonen S et al (2021) GFAP as a biomarker in frontotemporal
- dementia and primary psychiatric disorders: diagnostic and prognostic performance. *J Neurol*
- 684 *Neurosurg Psychiatry* 92: 1305-1312
- Katisko K, Cajanus A, Jaaskelainen O, Kontkanen A, Hartikainen P, Korhonen VE, Helisalmi S,
- Haapasalo A, Koivumaa-Honkanen H, Herukka SK et al (2020) Serum neurofilament light chain
- 687 is a discriminative biomarker between frontotemporal lobar degeneration and primary
- 688 psychiatric disorders. J Neurol 267: 162-167
- 689 Kmetzsch V, Anquetil V, Saracino D, Rinaldi D, Camuzat A, Gareau T, Jornea L, Forlani S,
- 690 Couratier P, Wallon D (2021) Plasma microRNA signature in presymptomatic and symptomatic
- 691 subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.
- 692 Journal of Neurology, Neurosurgery & Psychiatry 92: 485-493
- 693 Kohen R, Barlev J, Hornung G, Stelzer G, Feldmesser E, Kogan K, Safran M, Leshkowitz D
- 694 (2019) UTAP: User-friendly Transcriptome Analysis Pipeline. *BMC bioinformatics* 24: 154
- 695 Kozomara A, Griffiths-Jones S (2014) miRBase: annotating high confidence microRNAs using
- deep sequencing data. *Nucleic Acids Res* 42: D68-73
- 697 Krishnan G, Raitcheva D, Bartlett D, Prudencio M, McKenna-Yasek DM, Douthwright C,
- 698 Oskarsson BE, Ladha S, King OD, Barmada SJ et al (2022) Poly(GR) and poly(GA) in
- 699 cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. *Nat Commun* 13: 2799
- 700 Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L (2010) Altered expression of miR-17-
- 5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. *Eur J Immunol* 40:
- 702 888-898
- 703 Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD:
- 704 disrupted RNA and protein homeostasis. *Neuron* 79: 416-438
- 705 Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for
- 706 RNA-seg data with DESeg2. Genome Biol 15: 550
- Ludwig N, Fehlmann T, Kern F, Gogol M, Maetzler W, Deutscher S, Gurlit S, Schulte C, von
- 708 Thaler AK, Deuschle C et al (2019) Machine Learning to Detect Alzheimer's Disease from
- 709 Circulating Non-coding RNAs. Genomics Proteomics Bioinformatics 17: 430-440
- Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B,
- 711 Stähler C, Meese E et al (2016) Distribution of miRNA expression across human tissues.
- 712 Nucleic Acids Research 44: 3865-3877
- Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Himmelfarb J, Bansal
- 714 N, Lee S-I (2020) From local explanations to global understanding with explainable AI for trees.
- 715 Nature Machine Intelligence 2: 56-67
- 716 Magen I, Aharoni S, Yacovzada NS, Tokatly Latzer I, Alves CRR, Sagi L, Fattal-Valevski A,
- 717 Swoboda KJ, Katz J, Bruckheimer E et al (2022) Muscle microRNAs in the cerebrospinal fluid
- 718 predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy
- 719 patients. Eur J Neurol 29: 2420-2430
- 720 Magen I, Yacovzada NS, Yanowski E, Coenen-Stass A, Grosskreutz J, Lu CH, Greensmith L,
- 721 Malaspina A, Fratta P, Hornstein E (2021) Circulating miR-181 is a prognostic biomarker for
- 722 amyotrophic lateral sclerosis. *Nat Neurosci* 24: 1534-1541
- 723 Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G,
- 724 Nicolaou N, Simon-Sanchez J et al (2012) Frequency of the C9orf72 hexanucleotide repeat

- 725 expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-
- 726 sectional study. Lancet Neurol 11: 323-330
- 727 Malacarne C, Galbiati M, Giagnorio E, Cavalcante P, Salerno F, Andreetta F, Cagnoli C, Taiana
- 728 M, Nizzardo M, Corti S et al (2021) Dysregulation of Muscle-Specific MicroRNAs as Common
- 729 Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from
- 730 Animal Models and Human Patients. Int J Mol Sci 22
- 731 McCarthy J, Collins DL, Ducharme S (2018) Morphometric MRI as a diagnostic biomarker of
- 732 frontotemporal dementia: A systematic review to determine clinical applicability. Neuroimage
- 733 *Clin* 20: 685-696
- 734 McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, Work Group on
- 735 Frontotemporal D, Pick's D (2001) Clinical and pathological diagnosis of frontotemporal
- 736 dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch
- 737 Neurol 58: 1803-1809
- 738 Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC (2017) Imaging and fluid biomarkers in
- 739 frontotemporal dementia. *Nature Reviews Neurology* 13: 406
- Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ, van
- 741 der Flier WM, Teunissen CE, van Swieten JC, Pijnenburg YAL (2018) Clinical value of
- 742 neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology
- 743 90: e1231-e1239
- Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM (2014) MicroRNAs in Alzheimer's
- 745 disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol
- 746 Aging 35: 152-158
- Muller M, Kuiperij HB, Versleijen AA, Chiasserini D, Farotti L, Baschieri F, Parnetti L, Struyfs H,
- 748 De Roeck N, Luyckx J et al (2016) Validation of microRNAs in Cerebrospinal Fluid as
- Biomarkers for Different Forms of Dementia in a Multicenter Study. *J Alzheimers Dis* 52: 1321 1333
- 751 Nelson PT, Wang WX (2010) MiR-107 is reduced in Alzheimer's disease brain neocortex:
- 752 validation study. J Alzheimers Dis 21: 75-79
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T,
- 754 Grossman M, Clark CM et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration
- and amyotrophic lateral sclerosis. *Science* 314: 130-133
- 756 Ni J, Wang X, Chen S, Liu H, Wang Y, Xu X, Cheng J, Jia J, Zhen X (2015) MicroRNA let-7c-5p
- 757 protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia
- 758 activation. Brain Behav Immun 49: 75-85
- 759 Niikado M, Chrem-Mendez P, Itzcovich T, Barbieri-Kennedy M, Calandri I, Martinetto H, Serra
- 760 M, Calvar J, Campos J, Russo MJ et al (2019) Evaluation of Cerebrospinal Fluid Neurofilament
- Light Chain as a Routine Biomarker in a Memory Clinic. J Gerontol A Biol Sci Med Sci 74: 442-
- 762 445
- 763 Niwald M, Migdalska-Sek M, Brzezianska-Lasota E, Miller E (2017) Evaluation of Selected
- 764 MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to
- 765 Cognition, Depression, and Disability. J Mol Neurosci 63: 275-282
- 766 Oeckl P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, Diehl-Schmid J, Grimmer T,
- 767 Halbgebauer S, Kort AM, Lima M, Marques TM et al (2022) Serum GFAP differentiates
- 768 Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J
- 769 Neurol Neurosurg Psychiatry
- 770 Peters OM, Ghasemi M, Brown RH, Jr. (2015) Emerging mechanisms of molecular pathology in
- 771 ALS. J Clin Invest 125: 1767-1779
- Piscopo P, Grasso M, Puopolo M, D'Acunto E, Talarico G, Crestini A, Gasparini M, Campopiano
- 773 R, Gambardella S, Castellano AE et al (2018) Circulating miR-127-3p as a Potential Biomarker
- for Differential Diagnosis in Frontotemporal Dementia. J Alzheimers Dis 65: 455-464

- 775 Prado LGR, Rocha NP, de Souza LC, Bicalho ICS, Gomez RS, Vidigal-Lopes M, Braz NFT,
- 776 Vieira ELM, Teixeira AL (2018) Longitudinal assessment of clinical and inflammatory markers in
- patients with amyotrophic lateral sclerosis. J Neurol Sci 394: 69-74
- 778 Prendecki M, Florczak-Wyspianska J, Kowalska M, Ilkowski J, Grzelak T, Bialas K, Kozubski W,
- 779 Dorszewska J (2019) APOE genetic variants and apoE, miR-107 and miR-650 levels in
- 780 Alzheimer's disease. Folia Neuropathol 57: 106-116
- 781 Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, Paul A, Diaz-Cruz C,
- 782 Gholipour T, Glanz BI et al (2018) Correlating serum micrornas and clinical parameters in
- 783 amyotrophic lateral sclerosis. *Muscle Nerve* 58: 261-269
- 784 Ravnik-Glavač M, Glavač D (2020) Circulating RNAs as potential biomarkers in amyotrophic
- 785 lateral sclerosis. International journal of molecular sciences 21: 1714
- 786 Regev K, Healy BC, Khalid F, Paul A, Chu R, Tauhid S, Tummala S, Diaz-Cruz C, Raheja R,
- 787 Mazzola MA et al (2017) Association Between Serum MicroRNAs and Magnetic Resonance
- 788 Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol 74: 275-285
- 789 Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisakk P, Chitnis
- 790 T, Jagodic M *et al* (2018) Identification of MS-specific serum miRNAs in an international multicenter study. *Neurol Neuroimmunol Neuroinflamm* 5: e491
- Reichenstein I, Eitan C, Diaz-Garcia S, Haim G, Magen I, Siany A, Hoye ML, Rivkin N, Olender
- 793 T, Toth B et al (2019) Human genetics and neuropathology suggest a link between miR-218 and
- 794 amyotrophic lateral sclerosis pathophysiology. Science Translational Medicine 11: eaav5264
- 795 Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC,
- Telephone Teleph
- in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257-268
- 798 Ricci C, Marzocchi C, Battistini S (2018) MicroRNAs as biomarkers in amyotrophic lateral
- 799 sclerosis. *Cells* 7: 219

800 Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. Nat Rev

- 801 Neurosci 14: 248-264
- 802 Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V (2018) CSF neurofilament
- 803 proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. *J Neurol*
- 804 265: 510-521
- Saucier D, Wajnberg G, Roy J, Beauregard AP, Chacko S, Crapoulet N, Fournier S, Ghosh A,
- Lewis SM, Marrero A et al (2019) Identification of a circulating miRNA signature in extracellular
- vesicles collected from amyotrophic lateral sclerosis patients. *Brain Res* 1708: 100-108
- 808 Schneider R, McKeever P, Kim T, Graff C, van Swieten JC, Karydas A, Boxer A, Rosen H,
- 809 Miller BL, Laforce R, Jr. et al (2018) Downregulation of exosomal miR-204-5p and miR-632 as a
- 810 biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89: 851-858
- Sharaf-Eldin WE, Kishk NA, Gad YZ, Hassan H, Ali MAM, Zaki MS, Mohamed MR, Essawi ML
- 812 (2017) Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential
- 813 diagnosis of immune-mediated neuroinflammatory diseases. J Neurol Sci 383: 188-198
- 814 Sheikh-Bahaei N, Sajjadi SA, Pierce AL (2017) Current role for biomarkers in clinical diagnosis
- of Alzheimer disease and frontotemporal dementia. Current treatment options in neurology 19:
- 816 46
- 817 Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, Hurtig HI, Chen-
- 818 Plotkin A, Wolk DA, McCluskey LF et al (2017) Circulating brain-enriched microRNAs as novel
- 819 biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res
- 820 Ther 9: 89
- 821 Silva-Spinola A, Lima M, Leitao MJ, Duraes J, Tabuas-Pereira M, Almeida MR, Santana I,
- 822 Baldeiras I (2022) Serum neurofilament light chain as a surrogate of cognitive decline in
- 823 sporadic and familial frontotemporal dementia. Eur J Neurol 29: 36-46
- 824 Snowden JS, Neary D, Mann DM (2002) Frontotemporal dementia. Br J Psychiatry 180: 140-
- 825 143

- 826 Sproviero D, Gagliardi S, Zucca S, Arigoni M, Giannini M, Garofalo M, Olivero M, Dell'Orco M,
- 827 Pansarasa O, Bernuzzi S et al (2021) Different miRNA Profiles in Plasma Derived Small and
- Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. *Int J Mol Sci* 22
- 829 Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E,
- 830 Roberts-South A, Benatar M, HortobaGyi T et al (2017) Amyotrophic lateral sclerosis -
- frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral
- 832 Scler Frontotemporal Degener 18: 153-174
- 833 Sun L, Liu A, Zhang J, Ji W, Li Y, Yang X, Wu Z, Guo J (2018) miR-23b improves cognitive
- impairments in traumatic brain injury by targeting ATG12-mediated neuronal autophagy. Behav
- 835 Brain Res 340: 126-136
- Takahashi I, Hama Y, Matsushima M, Hirotani M, Kano T, Hohzen H, Yabe I, Utsumi J, Sasaki
- H (2015) Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral
- 838 Sclerosis. Mol Brain 8: 67
- 839 Tan YJ, Wong BYX, Vaidyanathan R, Sreejith S, Chia SY, Kandiah N, Ng ASL, Zeng L (2021)
- 840 Altered Cerebrospinal Fluid Exosomal microRNA Levels in Young-Onset Alzheimer's Disease
- and Frontotemporal Dementia. *J Alzheimers Dis Rep* 5: 805-813
- 842 Tasca E, Pegoraro V, Merico A, Angelini C (2016) Circulating microRNAs as biomarkers of
- muscle differentiation and atrophy in ALS. Clin Neuropathol 35: 22-30
- Teunissen CE, Elias N, Koel-Simmelink MJ, Durieux-Lu S, Malekzadeh A, Pham TV, Piersma
- SR, Beccari T, Meeter LH, Dopper EG et al (2016) Novel diagnostic cerebrospinal fluid
- 846 biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics.
- 847 Alzheimers Dement (Amst) 2: 86-94
- Thijssen EH, Verberk IMW, Kindermans J, Abramian A, Vanbrabant J, Ball AJ, Pijnenburg Y,
- 849 Lemstra AW, van der Flier WM, Stoops E et al (2022) Differential diagnostic performance of a
- panel of plasma biomarkers for different types of dementia. Alzheimers Dement (Amst) 14:
- 851 e12285
- Toivonen JM, Manzano R, Olivan S, Zaragoza P, Garcia-Redondo A, Osta R (2014) MicroRNA-
- 206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. *PLoS One* 9:
- 854 e89065
- Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis.
- 856 The Lancet Neurology 8: 94-109
- van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, Meeter LH, Dopper EG,
- 858 Papma JM, Heller C et al (2020) Neuronal pentraxin 2: a synapse-derived CSF biomarker in
- 859 genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry 91: 612-621
- 860 van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH
- 861 (2017) Amyotrophic lateral sclerosis. *Lancet* 390: 2084-2098
- Verde F, Otto M, Silani V (2021) Neurofilament Light Chain as Biomarker for Amyotrophic
- 863 Lateral Sclerosis and Frontotemporal Dementia. Front Neurosci 15: 679199
- Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, Kazoka M, Wollff H,
- 865 Heath PR, Shaw PJ (2017a) Serum miRNAs miR-206, 143-3p and 374b-5p as potential
- 866 biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiology of aging 55: 123-131
- Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, Kazoka M, Wollff H,
- Heath PR, Shaw PJ et al (2017b) Serum miRNAs miR-206, 143-3p and 374b-5p as potential
- 869 biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging 55: 123-131
- 870 Wang J, Chen C, Zhang Y (2020) An investigation of microRNA-103 and microRNA-107 as
- potential blood-based biomarkers for disease risk and progression of Alzheimer's disease. *J Clin*
- 872 Lab Anal 34: e23006
- Wang L, Zhang L (2020) Circulating microRNAs as diagnostic biomarkers for motor neuron
- 874 disease. Frontiers in neuroscience 14
- Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT (2008)
- 876 The expression of microRNA miR-107 decreases early in Alzheimer's disease and may

- accelerate disease progression through regulation of beta-site amyloid precursor proteincleaving enzyme 1. *J Neurosci* 28: 1213-1223
- Wilson KM, Katona E, Glaria I, Carcole M, Swift IJ, Sogorb-Esteve A, Heller C, Bouzigues A,
- Heslegrave AJ, Keshavan A et al (2022) Development of a sensitive trial-ready poly(GP) CSF
- 881 biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral
- 882 sclerosis. J Neurol Neurosurg Psychiatry 93: 761-771
- 883 Wingo TS, Yang J, Fan W, Min Canon S, Gerasimov ES, Lori A, Logsdon B, Yao B, Seyfried
- NT, Lah JJ et al (2020) Brain microRNAs associated with late-life depressive symptoms are also
- associated with cognitive trajectory and dementia. NPJ Genom Med 5: 6
- Witten IH, Frank E, Hall MA, Pal CJ (2017) Ensemble Learning. In: Data Mining (Fourth Edition),
- Witten I.H., Frank E., Hall M.A., Pal C.J. (eds.) pp. 479-501. Morgan Kaufmann:
- 888 Xu Z, Henderson RD, David M, McCombe PA (2016) Neurofilaments as Biomarkers for
- 889 Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *PLoS One* 11:
- 890 e0164625

- Yang D, Wang WZ, Zhang XM, Yue H, Li B, Lin L, Fu J (2014) MicroRNA expression aberration
- in Chinese patients with relapsing remitting multiple sclerosis. *J Mol Neurosci* 52: 131-137
- 893 Yilmaz SG, Erdal ME, Ozge AA, Sungur MA (2016) Can Peripheral MicroRNA Expression Data
- 894 Serve as Epigenomic (Upstream) Biomarkers of Alzheimer's Disease? OMICS 20: 456-461
- 895 Zhao XH, Wang YB, Yang J, Liu HQ, Wang LL (2019) MicroRNA-326 suppresses iNOS
- 896 expression and promotes autophagy of dopaminergic neurons through the JNK signaling by
- targeting XBP1 in a mouse model of Parkinson's disease. *J Cell Biochem* 120: 14995-15006

Main tables and Figures

| | Control | ALS | Control | FTD |
|--|---------------|-----------------|---------------|---------------|
| Number of subjects (% males) | 102 (28%) | 206 (59%) | 56 (46%) | 169 (65%) |
| Age at enrolment | 49.9±13.7 yr. | 64.4±11.0 yr. | 61.0±13.3 yr. | 65.6±8.4 yr. |
| Age of onset (1 st reported symptoms) | | 62.1±11.3 yr. | | 60.1±8.4 yr. |
| Disease duration at enrolment | | 28.2±30.7 m | | 67.0±41.4 m |
| ALSFRS-R at enrolment | | 36.0±8.1 | | |
| El-Escorial (Definite/probable/lab- supported/possible/suspected/other) | | 57/90/27/29/1/2 | | |
| Bulbar onset/total | | 64/206 | | |
| Riluzole treated / total | | 139/206 | | |
| ALS Family history / total | | 9/206 | | |
| C9ORF72 genetics/total | | 14/206 | | |
| FTD clinical subtype (bvFTD/PNFA/SD/FTD-ALS/others) | | | | 82/40/28/5/14 |
| FTD Mutation carriers (C9ORF72/MAPT/ GRN/TBK1) | | | | 18/14/13/2 |
| Likely FTD pathology (TDP-43/Tau) | | | | 63/19 |

Table 1. Summary of demographic and clinical characteristics of ALS and FTD cases and their respective control samples. ALSFRS-R: ALS functional rating scale. bvFTD: behavioural FTD; PNFA: progressive nonfluent aphasia; SD: semantic dementia. Mean±SD.

| Class/ Metric | Precision/ PPV | Sensitivity/ Recall | Specificity/ TNR | NPV | f1 | # samples |
|---------------|-------------------|------------------------|---------------------|-----|-----|-----------|
| Controls | 66% | 50% | 88% | 80% | 57% | 38 |
| FTD | 90% | 92% | 95% | 96% | 91% | 39 |
| ALS | 71% | 83% | 79% | 88% | 76% | 47 |
| macro avg | 75% | 75% | | | 75% | 124 |
| weighted avg | 75% | 76% | | | 75% | 124 |

Table 2. Performance summary of "one-vs-rest" multi-disease classifier




Figure 1. miRNA signature associated with ALS and FTD. MA plot of differential miRNA expression in (A) ALS patients (N=202) versus non-neurodegenerative controls (N=125); (B) FTD patients (N=168) versus non-neurodegenerative controls (N=125); (C) FTD versus ALS. Log 2 transformed fold change (y-axis), against mean miRNA abundance (x-axis). Red: significantly changed miRNAs (p<0.05, Wald test).




Figure 2: Diagnosis of FTD by a distinctive cell free miRNA signature.

- (A) Accuracy (AUC ROC, y-axis) as a function of the number of plasma miRNAs used in the FTD prediction model. Increasing numbers of miRNA features (x-axis) successively-elected in the recursive feature elimination process reveal an optimum at 13 features (blue line).
- (B) ROC curves in the training set: true positive rate (y-axis) vs. false positive rate (x-axis). Mean values and variance when data from 219 samples with 3-fold cross validation. Mean AUC 0.93 ± SD. 95% CI is 91%-95%.
- (C) Performance and generalizability on held-out data revealed by a ROC curve with AUC of 0.9 and average precision of 0.89.
- (D) Reliability diagram, plotting truly observed vs. predicted average probability in five bins reveals a sufficient calibrated model on the held-out set.
- (E) Confusion matrix showing the prediction errors on held out dataset. At a probability threshold of 60%, and 0.83 Negative predictive value (NPV), over 0.85 True Positive Rate (also, recall/ sensitivity) and 0.17 False Positive Rate. Specificity is 0.87 and 0.2 false discovery rate.
- (F) AUC ROC of a model trained with only a subset of top 13 most predictive features, reveals a stable performance with the selected final features.




Figure 3: The contribution of individual miRNAs to the predictor of FTD diagnosis.

(A) Mean absolute SHapley Additive exPlanations (SHAP) values break down the impact of specific miRNAs on FTD disease predictor output in the held-out cohort. (B) Illustration of the relationship between the miRNA levels (low - blue to high - red), SHAP values and the impact on the prediction in the held-out cohort




Figure 4: Diagnosis of ALS by a distinctive cell free miRNA signature.

- (A) Accuracy (AUC ROC, y-axis) as a function of the number of plasma miRNAs used in the ALS prediction model. Increasing numbers of miRNA features (x-axis) successively elected in the recursive feature elimination process reveal an optimum at 12 features (blue line).
- (B) ROC curves in the training set: true positive rate (y-axis) vs. false positive rate (x-axis). Mean values and variance when data from 245 samples with 3-fold cross validation. Mean AUC 0.86 ± SD. 95% CI is 82%-90%.
- (C) Performance and generalizability on held-out data revealed by a ROC curve with AUC of 0.78 and average precision of 0.82.
- (D) Reliability diagram, plotting truly observed vs. predicted average probability in five bins reveals a calibrated model on the held-out set.
- (E) Confusion matrix showing the prediction errors on held out dataset. At a probability threshold of 45%, 0.81 precision (PPV), 0.98 True Positive Rate (also, "recall"/"sensitivity") and 0.19 False Discovery Rate are demonstrated.
- (F) AUC ROC of a model trained with only a subset of top 12 most predictive features reveals a stable performance with the selected final features.




Figure 5: The contribution of individual miRNAs to the predictor of ALS diagnosis.

(A) Mean absolute SHapley Additive exPlanations (SHAP) values break down the impact of specific miRNAs on ALS disease predictor output in the held-out cohort. (B) Illustration of the relationship between the miRNA levels (low-blue to high-red), SHAP values and the impact on the prediction in the held-out cohort.




Figure 6: A multi-disease miRNA-based prediction model displays a superior diagnostic power over the binary models. A 3-fold cross-validated RFE with Extra Tree Classifier reveals that 16 features out of the original 132 approximate the same weighted mean one-vs-rest ROC AUC. (B) Fitting a Gradient Boosting multi-class classifier ("one-vs-all" strategy) on the training set. The multi-disease classifier achieved a weighted "one-vs-all" ROC AUC of 0.92, 0.91, 0.89 for each fold, respectively. Mean AUC of 90%±7% is obtained, indicating an overall good fit of the soft-classifier to all classes. Variance of the curve is shown in gray. (C) Model generalizability by ROC AUC per class in the held-out set (AUC of 0.76 for controls, 0.97 for FTD and 0.86 for ALS class), reassuring good accuracy for the soft-classifier over all three classes (micro-average AUC of 0.88 and macro-average AUC of 0.87), ensuring the model is not overfitting. (D) Confusion matrix (with a one-vs-rest strategy) in the held-out data. Interestingly, 15/19 control subjects that were falsely classified were classified as "ALS". It can be observed that of the 16 false positives in 'ALS' class, 93.75% were actually healthy control. (E) a Venn diagram of miRNAs shared in the three classification models.




Figure 7: The contribution of individual features miRNAs shared and disease-specific miRNA predictors. (A) SHAP analysis explains how features impact the multi-disease predictor output, namely, class probabilities. Average impact (mean absolute SHAP values) of miRNAs on model output for features, ordered according to their importance over all classes. (B-C) Combining feature importance with feature effects to illustrate the relationship between the value of the feature and the impact on the prediction, for a specific class; each point is a SHAP value for a feature and a specific subject. The position on the y-axis is determined by the feature and scattered on the x-axis by the SHAP value. The color represents the value of the feature from low (blue) to high (red). For example, the levels of mir-1-3p equally influence predictions of FTD and ALS, with negligible contribution to predicting 'controls'. miR-326 and mir-629-5p contributes to the FTD predictor more than ALS, whilst high expression of mir-206 increases the predicted ALS risk (while having no effect on the risk of FTD). High values of miR-326, a miRNA inflammatory regulator, increases the predicted FTD risk while miR-185-5p has the reversed impact with higher values reducing the risk of FTD.




Figure 8. AUC values for different miRNA classifiers for discriminating FTD vs control (A) and ALS vs controls (B) in the held-out data. The classifiers used in (A) were either the 13 selected in the FTD model in our data, a combination of miR-34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p selected in Kmetzsch et al., 2020 (Kmetzsch et al., 2021), or a combination of miR-335/let-7e, miR-99b/let-7e and miR-9-3p/miR-181a selected in Sheinerman et al., 2017 (Sheinerman et al., 2017); the classifiers used in (B) were either the 12 selected in the ALS model in our data, a combination of miR-34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p selected in Kmetzsch et al., 2020 or a combination of miR-206/miR-31, miR-206/miR-125b and miR-99/miR-338-3p, selected in Sheinerman et al., 2017.

Supplementary tables and figures

| | Before Exclusion | | | 4 | After Exclus | sion | |
|-----------------|--------------------------|-----|----------|---------------|--------------|---------------|--|
| Group Name | Age | Sex | Mean Age | Group Size | Mean Age | Group Size | Age |
| ALS cases | 04.4 <u>1</u> 11.01, | F | 65.9 | 84 | 66.6 | 82 | 64.9±10.4, 95% CI [63.47, 66.35] |
| (n=206) | | М | 63.3 | 122 | 63.8 | 120 | |
| ALS controls | 95% CI [47.25, 52.55] | F | 51.1 | 73 | 55.3 | 59 | 55.7±10, 95% CI [53.46, 57.94] |
| (n=102) | | М | 46.8 | 29 | 57.0 | 18 | [55.46, 57.94] |
| FTD cases | [64.32, 66.84] | F | 66.8 | 59 | 67.3 | 58 | 65.75 <u>+</u> 8.1, 95% CI |
| (n=169) | | М | 64.9 | 110 | 64.9 | 110 | [64.53, 66.97] |
| FTD controls | 00.30 <u>-</u> | F | 61.1 | 30 | 65.6 | 26 | 65.55 <u>+</u> 7.3, 95% CI |
| (n= 56) | | M | 60.8 | 26 | 65.6 | 22 | [63.49, 67.61] |

Supplementary Table 1. Age and sex characteristics - before and after exclusion by age (age-based QC)

| Predictor | Single Feature AUC |
|-------------|--------------------|
| miR-423-5p | 0.69 |
| miR-125b-5p | 0.69 |
| miR-26a-5p | 0.68 |
| miR-107 | 0.68 |
| miR-185-5p | 0.64 |
| miR-629-5p | 0.62 |
| let-7d-3p | 0.61 |
| miR-379-5p | 0.61 |
| miR-361-5p | 0.6 |
| let-7c-5p | 0.6 |
| miR-326 | 0.58 |
| miR-378a-3p | 0.56 |
| miR-484 | 0.55 |


Supplementary Table 2. Predictive power of selected features when used as a single predictor for FTD on held-out data. Among the most predictive features are miRNAs expressed in the brain, such as miR-26a-5p, miR-125b-5p and let-7c-5p.

| Predictor | Single Feature AUC |
|-------------|--------------------|
| miR-186-5p | 0.75 |
| miR-223-3p | 0.73 |
| miR-23b-3p | 0.72 |
| miR-454-3p | 0.72 |
| miR-1-3p | 0.71 |
| miR-206 | 0.65 |
| miR-103a-3p | 0.62 |
| miR-185-5p | 0.61 |
| miR-370-3p | 0.56 |
| miR-181b-5p | 0.54 |
| let-7i-5p | 0.44 |
| miR-320a | 0.39 |


 Supplementary Table 3. Predictive power of selected features, when used as a single predictor for ALS diagnosis on held-out data.

| Predictor | Single Feature weighted one-vsall AUC |
|-------------|---------------------------------------|
| miR-1-3p | 0.71 |
| miR-185-5p | 0.7 |
| miR-186-5p | 0.69 |
| miR-629-5p | 0.65 |
| miR-206 | 0.65 |
| miR-423-3p | 0.65 |
| miR-378a-3p | 0.62 |
| let-7d-3p | 0.62 |
| miR-339-5p | 0.61 |
| miR-23b-3p | 0.6 |
| miR-484 | 0.58 |
| miR-148a-3p | 0.57 |
| miR-107 | 0.57 |
| miR-361-5p | 0.56 |
| miR-326 | 0.55 |
| miR-24-3p | 0.45 |

Supplementary Table 4. List of most predictive features and their predictive power (on held-out data) when used as a single predictor for ALS-FTD



Supplementary Figure 1: QC of prognostic factors in the meta-cohort. Depicting heterogeneity of prognostic factors in the four different groups in the study, before (upper) and after (lower) exclusion of 38 outlier subjects under the age of 40. While the univariate distribution of age in some sub-groups overlap, the difference in the shape of the age distributions may reflect a possible bias induced by age (B). The total standardized differences in mean age across sub-groups was reduced by 68% after exclusion. (A), (D) Boxplot age quartiles and variation of subjects by group - indicating skewness and variability outside the upper and lower quartiles of age in some groups. After outlier exclusion, the groups "ALS-ctr" and "FTD ctr" are more comparable and the high variability in "FTD ctr" is reduced. (B), (E) Distribution of age conditioned by group: estimating the shape of the Probability Density Function (PDF) of age by non-parametric Gaussian kernel density estimate. Outlier removal has increased the overlap of the different PDFs. (C), (F) Mean age conditioned by gender and group. The different groups in the study are more balanced in terms of age and gender after age-outlier removal.



Supplementary Figure 2. t-SNE analysis of control subjects (A) and all subjects (B) presenting deseparation between different control groups and between disease groups and merged control group.